Predictors Of Left Ventricular Systolic Function Recovery After Transcatheter Aortic Valve Replacement

Sponsor
Assiut University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05069168
Collaborator
(none)
30
1
13
2.3

Study Details

Study Description

Brief Summary

Investigate the preprocedural predictors of left ventricular systolic function Recovery after TAVR

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Echocardiography before and after TAVR

Detailed Description

Calcific aortic stenosis (AS) is the most common valve disease in the western world requiring intervention,Although Surgical Aortic Valve Replacement (SAVR) was considered as the first therapeutic method, approximately one-third of AS patients cannot undergo SAVR due to its' high risk or contraindication.

Since Transcatheter Aortic Valve Replacement (TAVR)was performed for the first time in 2002,TAVR has emerged as a growing prevalent treatment on severe symptomatic AS with the procedure initially performed on the inoperable patients with intermediate and high risks.

Recently, the Food and Drug Administration had approved it on low-risk symptomatic subjects.

AS has to be considered a disease of the left ventricle (LV) rather than purely affecting the aortic valve, Approximately one-third of patients with severe symptomatic AS have LV systolic dysfunction .

Recovery of LV ejection fraction (LVEF) is associated with improvements in clinical outcomes after TAVR as shown by a lot of studies.

The Placement of Aortic Transcatheter Valves (PARTNER) trial demonstrated that recovery of LV function in patients with severe symptomatic AS and LV systolic dysfunction who underwent TAVR, occurs in 40% to 50% of patients .

Higher trans-aortic mean pressure gradient , less LV hypertrophy, Less LV fibrosis and absence of AF are predictors of recovery of LV function after TAVR .

However, there is still a scanty data about the predictors of LV function recovery after TAVR.

Study Design

Study Type:
Observational
Anticipated Enrollment :
30 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
Predictors Of Left Ventricular Systolic Function Recovery After Transcatheter Aortic Valve
Anticipated Study Start Date :
Apr 1, 2023
Anticipated Primary Completion Date :
Jan 30, 2024
Anticipated Study Completion Date :
Apr 30, 2024

Arms and Interventions

Arm Intervention/Treatment
LVEFrecovery

patient who shows improvement of left ventricular systolic function

Diagnostic Test: Echocardiography before and after TAVR
Evaluation of severity of aortic stenosis using :peak velocity ,peak and mean pressure gradient and aortic valve area by continuity equation.-Evaluation of left ventricular dimensions ,volumes and systolic function as assessed by ejection fraction (EF) by m-mode and biplane simpson's method at apical 4 and 2 chambers view Speckle tracking echocardiography(STE) Apical four-, three-, and two-chamber views were used to obtain longitudinal and circumferential strain before and follow-up after TAVR. cardiac CT :Routine full protocol before TAVR for evaluation and Detection and calculation of left ventricular fibrosis using extracellular volume. Coronary angiography:evaluate the presence of CAD and calculation of syntax score(SS)
Other Names:
  • cardiac computed tomography and coronary angiography
  • Non LVEF recovery

    patient who don't show improvement of left ventricular systolic function

    Diagnostic Test: Echocardiography before and after TAVR
    Evaluation of severity of aortic stenosis using :peak velocity ,peak and mean pressure gradient and aortic valve area by continuity equation.-Evaluation of left ventricular dimensions ,volumes and systolic function as assessed by ejection fraction (EF) by m-mode and biplane simpson's method at apical 4 and 2 chambers view Speckle tracking echocardiography(STE) Apical four-, three-, and two-chamber views were used to obtain longitudinal and circumferential strain before and follow-up after TAVR. cardiac CT :Routine full protocol before TAVR for evaluation and Detection and calculation of left ventricular fibrosis using extracellular volume. Coronary angiography:evaluate the presence of CAD and calculation of syntax score(SS)
    Other Names:
  • cardiac computed tomography and coronary angiography
  • Outcome Measures

    Primary Outcome Measures

    1. left ventricular systolic function recovery by ejection fraction [30 days post TAVR]

      absolute increase of ≥10% in EF compared with baseline

    2. left ventricular systolic function recovery by STE [30 days post TAVR]

      Myocardial recovery by STE is defined as a ≥20% relative increase in the magnitude of global longitudinal strain compared with baseline

    Secondary Outcome Measures

    1. Quality of life assessment [30days post TAVR]

      NIHA class .

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • patients with symptomatic severe aortic stenosis eligible for TAVR with LV systolic function less than 50%.
    Exclusion Criteria:
    • Severe Rheumatic or degenerative mitral regurgitation.

    • Previous Valve Replacement.

    • Previous myocardial infarction.

    • Previous Coronary Artery By Bass Graft (CABG)Surgery.

    • Post TAVR significant paravalvular leakage

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Medicine Assiut Egypt

    Sponsors and Collaborators

    • Assiut University

    Investigators

    • Study Director: Hatem A Helmy, Assiut University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Anwar S Helen, Principle investigator, Assiut University
    ClinicalTrials.gov Identifier:
    NCT05069168
    Other Study ID Numbers:
    • TAVR
    First Posted:
    Oct 6, 2021
    Last Update Posted:
    Jul 20, 2022
    Last Verified:
    Sep 1, 2021
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 20, 2022